Document:

Exhibit 10.5

 

CONSULTANT AGREEMENT

 

This Consultant Agreement (the “Agreement”) is made
and entered into as of July 16, 2021, by and between William Caragol (the “Consultant”) and Mainz Biomed B.V. (the
“Company”).

 

WHEREAS, the Company desires to for the Consultant to provide
services on the terms and conditions set forth herein; and

 

WHEREAS, the Consultant desires to be employed by the Company
on such terms and conditions.

 

NOW, THEREFORE, in consideration of the mutual covenants, promises,
and obligations set forth herein, the parties agree as follows:

 

1. Term.
The Consultant shall serve as the Chief Financial Officer of the Company and to assist the Company, among other things, in (i) the preparation
and review of financial statements and forecasts, and (ii) the preparation and review of the Company’s proposed registration statement
on Form F-1, and (iii) all other service typically performed by a Chief Financial Officer (the “Services”) . This Agreement
shall be effective as of the date hereof, 2021 (the “Effective Date”). The period during which the Consultant is employed
by the Company hereunder is hereinafter referred to as the “Consulting Term.”

 

2. Position
and Duties.

 

2.1 Position. During the
Consulting Term, the Consultant shall report to the Company’s Chief Executive Officer and the Chairperson of the Board of Directors.
In providing the Services, the Consultant shall have such duties, authority, and responsibilities as shall be determined from time to
time by the CEO and the Board of Directors.

 

2.2 Duties. During the Consulting
Term, the Consultant will not engage in any other business, profession, or occupation for compensation or otherwise which would conflict
or interfere with the performance of the Services either directly or indirectly without the prior written consent of the Board. The Consultant
has disclosed to the Company all of his other business interests and it was mutually agreed that these interests do not conflict with
the performance of the Services.

 

3. Place
of Performance. The principal place of Consultant’s service shall be mutually agreed by the Consultant and the CEO, provided
that, the Consultant will be required to make frequent visits to the Company’s various facilities and may be required to travel
on Company business during the Consulting Term. The Consultant shall be responsible for the cost of maintaining his workspace or office
at and the costs of operating such office.

 

4. Compensation.

 

4.1  Base Compensation.
For the Services, the Company shall pay to the Consultant $15,000 per month (the “Base Compensation”) due hereunder
in periodic installments in accordance with the Company’s customary practices and applicable laws, but no less frequently than monthly.

 

4.2 Equity Compensation.
On the date of the IPO, the Employee shall be granted options to acquire at the price per ordinary share in the IPO, options (“IPO
Options”) to acquire a number of ordinary shares that will equal one percent (1%) of the outstanding ordinary shares immediately
following the IPO. The IPO Options are to be granted pursuant to a Stock Option Plan that has been approved by the Board of Directors
and shareholders of the Company and will vest over 4 years from the Effective Date in equal monthly installments, provided that the Company’s
Board of Directors and the Consultant shall use their best efforts to agree to milestones pursuant to which the number of IPO Options
equal to 50% of (i) the all IPO Options less (ii) those IPO Options that vested as of the date such milestones are met shall immediately
vest (and shall equally reduce the amount of IPO options to vest each month pursuant to this section).

 

    1

     

    

 

4.3 Business Expenses. The
Consultant shall be entitled to reimbursement for all reasonable and necessary out-of-pocket business, entertainment, and travel expenses
incurred by the Consultant in connection with the performance of the Consultant’s duties hereunder in accordance with the Company’s
expense reimbursement policies and procedures; provided that any expense above $1,500 shall be first approved by the CEO.

 

4.4  Indemnification.
In the event that the Consultant is made a party or threatened to be made a party to any action, suit, or proceeding, whether civil, criminal,
administrative, or investigative (a “Proceeding”), other than any Proceeding initiated by the Consultant or the Company
related to any contest or dispute between the Consultant and the Company or any of its affiliates with respect to this Agreement or the
Consultant’s service hereunder, by reason of the fact that the Consultant is or was a director or officer of the Company, or any
affiliate of the Company, or is or was serving at the request of the Company as a director, officer, member, Consultant, or agent of another
corporation or a partnership, joint venture, trust, or other enterprise, the Consultant shall be indemnified and held harmless by the
Company to the fullest extent applicable to any other officer or director of the Company from and against any liabilities, costs, claims,
and expenses, including all costs and expenses incurred in defense of any Proceeding (including attorneys’ fees).

 

4.5  Clawback Provisions.
Any amounts payable under this Agreement are subject to any applicable law, government regulation, or stock exchange listing requirement
providing for clawback or recovery of amounts that were paid to the Consultant.

 

5. Termination of Consultant.
The Consulting Term and the Consultant’s service hereunder may be terminated by either the Company or the Consultant at any time
and for any reason; provided that, unless otherwise provided herein, either party shall be required to give the other party at least 10
(ten) days advance written notice of any termination of the Consultant’s service. Upon termination of the Consultant’s service
during the Consulting Term, the Consultant shall be entitled to the compensation and benefits described in this Section 5 and shall have
no further rights to any compensation or any other benefits from the Company or any of its affiliates.

 

5.1  Expiration of
the Term, For Cause or Without Good Reason.

 

(a) The
Consultant’s service hereunder may be terminated by the expiration of the Consulting Term, by Company for Cause or by the Consultant
without Good Reason. If the Consultant’s service is terminated upon the expiration of the Consulting Term, by the Company for Cause
or by the Consultant without Good Reason, the Consultant shall be entitled to receive within two (2) weeks following the Termination Date
(as defined below):

 

		(i)	any accrued but unpaid Base Compensation;

 

		(ii)	reimbursement for unreimbursed business expenses properly
incurred by the Consultant, which shall be subject to and paid in accordance with the Company’s expense reimbursement policy; and

 

Items 5.1(a)(i) through 5.1(a)(ii) are
referred to herein collectively as the “Accrued Amounts”.

 

(b) For purposes of this
Agreement, “Cause” shall mean:

 

		(i)	the Consultant’s failure to perform Consultant’s
duties (other than any such failure resulting from incapacity due to physical or mental illness);

 

		(ii)	the Consultant’s failure to comply with any valid and legal directive of the Board;

 

    2

     

    

 

		(iii)	the Consultant’s engagement in dishonesty, illegal conduct, or misconduct, which is, in each case,
injurious to the Company or its affiliates;

 

		(iv)	the Consultant’s embezzlement, misappropriation, or fraud, whether or not related to the Consultant’s
service with the Company and whether or not occurring during the Consulting Term;

 

		(v)	the Consultant’s conviction of or plea of guilty or nolo contendere to a crime that constitutes
a felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude;

 

		(vi)	the Consultant’s violation of a material policy of the Company;

 

		(vii)	the Consultant’s unauthorized disclosure of Confidential Information (as defined below);

 

		(viii)	the Consultant’s material breach of any material obligation under this Agreement or any other written
agreement between the Consultant and the Company; or

 

		(ix)	any material failure by the Consultant to comply with the Company’s written policies or rules, as
they may be in effect from time to time during the Consulting Term.

 

(c) For
purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following, in each case during the
Consulting Term without the Consultant’s written consent:

 

		(i)	a material reduction in the Consultant’s Base Compensation (other than a general reduction in Base
Compensation that affects all similarly situated consultants in substantially the same proportions);

 

		(ii)	any material breach by the Company of any material provision of this Agreement or any material provision
of any other agreement between the Consultant and the Company;

 

The Consultant cannot terminate Consultant’s
service for Good Reason unless Consultant has provided written notice to the Company of the existence of the circumstances providing grounds
for termination for Good Reason within 10 (ten) days of the initial existence of such grounds and the Company has had at least 10 (ten)
days from the date on which such notice is provided to cure such circumstances. If the Consultant does not terminate Consultant’s
service for Good Reason within 10 (ten) days after the first occurrence of the applicable grounds, then the Consultant will be deemed
to have waived Consultant’s right to terminate for Good Reason with respect to such grounds.

 

5.2 Termination Without Cause
or for Good Reason. The Consulting Term and the Consultant’s service hereunder may be terminated by the
Consultant for Good Reason or by the Company without Cause. In the event of such termination, the Consultant shall be entitled to receive
the Accrued Amounts and subject to the Consultant’s compliance with Section 6, Section 7, Section
8, and Section 9 of this Agreement and the Consultant’s execution of a release of claims in favor
of the Company, its affiliates and their respective officers and directors in a form provided by the Company (the “Release”)
and such Release becoming effective within 60 days following the Termination Date (such 60-day period, the “Release Execution
Period”), the Consultant shall be entitled to receive the following:

 

 (a) equal installment payments payable in accordance with the Company’s normal payroll practices, but no less frequently than monthly, which are in the aggregate equal to 1 (one) times the sum of the Consultant’s Base Compensation for the year in which the Termination Date occurs, which shall begin within 30 (thirty) days following the Termination Date; provided that, the first installment payment shall include all amounts that would otherwise have been paid to the Consultant during the period beginning on the Termination Date and ending on the first payment date if no delay had been imposed;

 

    3

     

    

 

 (b) Accelerated vesting for any stock options outstanding at the time of the Termination Date that would have vested in the six months following the Termination Date.

 

5.3 Death or Disability.

 

(a) The
Consultant’s service hereunder shall terminate automatically upon the Consultant’s death during the Consulting Term, and the
Company may terminate the Consultant’s service on account of the Consultant’s Disability.

 

(b) If
the Consultant’s service is terminated during the Consulting Term on account of the Consultant’s death or Disability, the
Consultant (or the Consultant’s estate and/or beneficiaries, as the case may be) shall be entitled to receive the Accrued Amounts.
Notwithstanding any other provision contained herein, all payments made in connection with the Consultant’s Disability shall be
provided in a manner which is consistent with federal and state law.

 

(c) For
purposes of this Agreement, “Disability” shall mean the Consultant’s inability, due to physical or mental incapacity,
to perform the essential functions of Consultant’s job, with or without reasonable accommodation, for one hundred eighty (180) days
out of any three hundred sixty-five (365) day period or one hundred twenty (120) consecutive days. Any question as to the existence of
the Consultant’s Disability as to which the Consultant and the Company cannot agree shall be determined in writing by a qualified
independent physician mutually acceptable to the Consultant and the Company. If the Consultant and the Company cannot agree as to a qualified
independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination
in writing. The determination of Disability made in writing to the Company and the Consultant shall be final and conclusive for all purposes
of this Agreement.

 

5.4  Notice of Termination.
Any termination of the Consultant’s service hereunder by the Company or by the Consultant during the Consulting Term (other than
termination pursuant to Section 5.3(a) on account of the Consultant’s death) shall be communicated by written notice of termination
(“Notice of Termination”) to the other party hereto in accordance with Section 27. The Notice of Termination shall
specify:

 

(a) The
termination provision of this Agreement relied upon;

 

(b) To
the extent applicable, the facts and circumstances claimed to provide a basis for termination of the Consultant’s service under
the provision so indicated; and

 

(c) The
applicable Termination Date.

 

5.5  Termination Date.
The Consultant’s “Termination Date” shall be:

 

(a)  If the Consultant’s
service hereunder terminates on account of the Consultant’s death, the date of the Consultant’s death;

 

(b) If
the Consultant’s service hereunder is terminated on account of the Consultant’s Disability, the date that it is determined
that the Consultant has a Disability;

 

(c)  If the Company terminates
the Consultant’s service hereunder for Cause, the date the Notice of Termination is delivered to the Consultant;

 

    4

     

    

 

(d) If
the Company terminates the Consultant’s service hereunder without Cause, the date specified in the Notice of Termination, which
shall be no less than 10 (ten) days following the date on which the Notice of Termination is delivered; provided that, the Company shall
have the option to provide the Consultant with a lump sum payment equal to 10 (ten) days’ Base Compensation in lieu of such notice,
which shall be paid in a lump sum on the Consultant’s Termination Date and for all purposes of this Agreement, the Consultant’s
Termination Date shall be the date on which such Notice of Termination is delivered;

 

(e) If
the Consultant terminates Consultant’s service hereunder with or without Good Reason, the date specified in the Consultant’s
Notice of Termination, which shall be no less than 10 (ten) days following the date on which the Notice of Termination is delivered; provided
that, the Company may waive all or any part of the 10 (ten) day notice period for no consideration by giving written notice to the Consultant
and for all purposes of this Agreement, the Consultant’s Termination Date shall be the date determined by the Company; and

 

Notwithstanding anything contained
herein, the Termination Date shall not occur until the date on which the Consultant incurs a “separation from service” within
the meaning of Section 409A.

 

5.6  Resignation of
All Other Positions. Upon termination of the Consultant’s service hereunder for any reason, the Consultant shall be deemed to
have resigned from all positions that the Consultant holds as an officer or member of the Board (or a committee thereof) of the Company
or any of its affiliates (unless otherwise agreed to by a majority of the Board).

 

6. Cooperation. The parties
agree that certain matters in which the Consultant will be involved during the Consulting Term may necessitate the Consultant’s
cooperation in the future. Accordingly, following the termination of the Consultant’s service for any reason, to the extent reasonably
requested by the Board, the Consultant shall cooperate with the Company in connection with matters arising out of the Consultant’s
service to the Company; provided that, the Company shall make reasonable efforts to minimize disruption of the Consultant’s other
activities. The Company shall reimburse the Consultant for reasonable expenses incurred in connection with such cooperation and, to the
extent that the Consultant is required to spend substantial time on such matters, the Company shall compensate the Consultant at a rate
based on the Consultant’s Base Compensation on the Termination Date.

 

7.  Confidential Information. The
Consultant understands and acknowledges that during the Consulting Term, Consultant will have access to and learn about Confidential Information,
as defined below.

 

7.1  Confidential
Information Defined.

 

(a) Definition.

 

For purposes of this Agreement, “Confidential
Information” includes, but is not limited to, all information not generally known to the public, in spoken, printed, electronic
or any other form or medium, including that relating directly or indirectly to: business processes, practices, methods, policies, plans,
publications, documents, research, operations, service, strategies, techniques, agreements, contracts, terms of agreements, transactions,
potential transactions, negotiations, pending negotiations, know-how, trade secrets, computer programs, computer software, applications,
operating systems, software design, web design, work-in-process, databases, manuals, records, articles, systems, material, sources of
material, supplier information, vendor information, financial information, results, accounting information, accounting records, legal
information, marketing information, advertising information, pricing information, credit information, design information, payroll information,
staffing information, personnel information, Consultant lists, supplier lists, vendor lists, developments, reports, internal controls,
security procedures, graphics, drawings, sketches, market studies, sales information, revenue, costs, formulae, notes, communications,
algorithms, product plans, designs, styles, models, ideas, audiovisual programs, inventions, unpublished patent applications, original
works of authorship, discoveries, experimental processes, experimental results, specifications, customer information, customer lists,
client information, client lists, manufacturing information, factory lists, distributor lists, and buyer lists of the Company Group or
its businesses or any existing or prospective customer, supplier, investor or other associated third party, or of any other person or
entity that has entrusted information to the Company Group in confidence.

 

    5

     

    

 

The Consultant understands that the
above list is not exhaustive, and that Confidential Information also includes other information that is marked or otherwise identified
as confidential or proprietary, or that would otherwise appear to a reasonable person to be confidential or proprietary in the context
and circumstances in which the information is known or used.

 

The Consultant understands and agrees
that Confidential Information includes information developed by Consultant in the course of Consultant’s service to the Company
as if the Company furnished the same Confidential Information to the Consultant in the first instance. Confidential Information shall
not include information that is generally available to and known by the public at the time of disclosure to the Consultant; provided that,
such disclosure is through no direct or indirect fault of the Consultant or person(s) acting on the Consultant’s behalf.

 

(b)  Company Creation
and Use of Confidential Information.

 

The Consultant understands and acknowledges
that the Company and its affiliates (the “Group”) have invested, and continue to invest, substantial time, money, and specialized
knowledge into researching, developing and commercializing its property and assets. The Consultant understands and acknowledges that as
a result of these efforts, the Company has created, and continues to use and create Confidential Information. This Confidential Information
provides them with a competitive advantage over others in the marketplace.

 

(c)  Disclosure and
Use Restrictions.

 

The Consultant agrees and covenants:
(i) to treat all Confidential Information as strictly confidential; (ii) not to directly or indirectly disclose, publish, communicate,
or make available Confidential Information, or allow it to be disclosed, published, communicated, or made available, in whole or part,
to any entity or person whatsoever (including other Consultants of the Group) not having a need to know and authority to know and use
the Confidential Information in connection with the business of the Group and, in any event, not to anyone outside of the direct employ
of the Group except as required in the performance of the Consultant’s authorized Consulting duties to the Company or with the prior
consent of the Board acting on behalf of the Group in each instance (and then, such disclosure shall be made only within the limits and
to the extent of such duties or consent); and (iii) not to access or use any Confidential Information, and not to copy any documents,
records, files, media, or other resources containing any Confidential Information, or remove any such documents, records, files, media,
or other resources from the premises or control of the Group, except as required in the performance of the Consultant’s authorized
Consulting duties to the Company or with the prior consent of the Board acting on behalf of the Group in each instance (and then, such
disclosure shall be made only within the limits and to the extent of such duties or consent). Nothing herein shall be construed to prevent
disclosure of Confidential Information as may be required by applicable law or regulation, or pursuant to the valid order of a court of
competent jurisdiction or an authorized government agency, provided that the disclosure does not exceed the extent of disclosure required
by such law, regulation, or order. The Consultant shall promptly provide written notice of any such order to the Board.

 

8. Restrictive Covenants.

 

8.1  Acknowledgement.
The Consultant understands that the nature of the Consultant’s position gives Consultant access to and knowledge of Confidential
Information and places Consultant in a position of trust and confidence with the Group. The Consultant understands and acknowledges that
the intellectual or artistic and other service Consultant provides to the Group are unique, special, or extraordinary because of the unique
nature of the automotive and manufacturing industries.

 

    6

     

    

 

The Consultant further understands
and acknowledges that the Group’s ability to reserve these for the exclusive knowledge and use of the Group is of great competitive
importance and commercial value to the Group, and that improper use or disclosure by the Consultant is likely to result in unfair or unlawful
competitive activity.

 

8.2  Non-Competition.
Because of the Group’s legitimate business interest as described herein and the good and valuable consideration offered to the Consultant,
during the Consulting Term and for the six months, to run consecutively, beginning on the last day of the Consultant’s service with
the Company, for any reason or no reason and whether Consulting is terminated at the option of the Consultant or the Group, the Consultant
agrees and covenants not to engage in Prohibited Activity.

 

For purposes of this Section 8, “Prohibited
Activity” is activity in which the Consultant contributes Consultant’s knowledge, directly or indirectly, in whole or
in part, as an Consultant, employer, owner, operator, manager, advisor, consultant, agent, Consultant, partner, director, stockholder,
officer, volunteer, intern, or any other similar capacity to an entity engaged in the same or similar business as the Group, including
those engaged in the pharmaceutical industry or the material businesses of the Company as set out in its filings with the U.S. Securities
and Exchange Commission. Prohibited Activity also includes activity that may require or inevitably requires disclosure of trade secrets,
proprietary information, or Confidential Information.

 

Nothing herein shall prohibit the Consultant
from purchasing or owning less than five percent (5%) of the publicly traded securities of any corporation, provided that such ownership
represents a passive investment and that the Consultant is not a controlling person of, or a member of a group that controls, such corporation.

 

This Section 8 does not, in any way,
restrict or impede the Consultant from exercising protected rights to the extent that such rights cannot be waived by agreement or from
complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency,
provided that such compliance does not exceed that required by the law, regulation, or order. The Consultant shall promptly provide written
notice of any such order to the Board.

 

8.3 Non-Solicitation
of Consultants. The Consultant agrees and covenants not to directly or indirectly solicit, hire, recruit, attempt to hire or recruit,
or induce the termination of Consulting of any Consultant of the Group during eighteen (18) months, to run consecutively, beginning on
the last day of the Consultant’s service with the Company.

 

8.4 Non-Solicitation
of Customers. The Consultant understands and acknowledges that because of the Consultant’s experience with and relationship
to the Group, Consultant will have access to and learn about much or all of the Group’s customer information. “Customer
Information” includes, but is not limited to, names, phone numbers, addresses, e-mail addresses, order history, order preferences,
chain of command, pricing information, and other information identifying facts and circumstances specific to the customer and relevant
to sales and/or service.

 

The Consultant understands and acknowledges
that loss of this customer relationship and/or goodwill will cause significant and irreparable harm.

 

The Consultant agrees and covenants,
during twenty-four (24) months, to run consecutively, beginning on the last day of the Consultant’s service with the Company, not
to directly or indirectly solicit, contact (including but not limited to e-mail, regular mail, express mail, telephone, fax, and instant
message), attempt to contact, or meet with the Company’s current, former or prospective customers for purposes of offering or accepting
goods or service similar to or competitive with those offered by the Company.

 

    7

     

    

 

9.  Non-Disparagement. The
Consultant and Company mutually agree and covenants that they will not at any time make, publish or communicate to any person or entity
or in any public forum any defamatory or disparaging remarks, comments, or statements concerning the Group or its businesses, or any of
its Consultants, officers, and existing and prospective customers, suppliers, investors and other associated third parties.

 

This Section 9 does not, in any way, restrict
or impede the Consultant from exercising protected rights to the extent that such rights cannot be waived by agreement or from complying
with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided
that such compliance does not exceed that required by the law, regulation, or order. The Consultant shall promptly provide written notice
of any such order to the Board.

 

10.  Acknowledgement. The
Consultant acknowledges and agrees that the service to be rendered by Consultant to the Company are of a special and unique character;
that the Consultant will obtain knowledge and skill relevant to the Company’s industry, methods of doing business and marketing
strategies by virtue of the Consultant’s service; and that the restrictive covenants and other terms and conditions of this Agreement
are reasonable and reasonably necessary to protect the legitimate business interest of the Group.

 

The Consultant further acknowledges that the amount
of Consultant’s compensation reflects, in part, Consultant’s obligations and the Company’s rights under Section 7, Section
8, and Section 9 of this Agreement; that Consultant has no expectation of any additional compensation, royalties or other payment of any
kind not otherwise referenced herein in connection herewith; and that Consultant will not be subject to undue hardship by reason of Consultant’s
full compliance with the terms and conditions of Section 7, Section 8, and Section 9 of this Agreement or the Company’s enforcement
thereof.

 

11.  Remedies. In the event
of a breach or threatened breach by the Consultant of Section 7, Section 8, or Section 9 of this Agreement, the Consultant hereby consents
and agrees that the Company shall be entitled to seek, in addition to other available remedies, a temporary or permanent injunction or
other equitable relief against such breach or threatened breach from any court of competent jurisdiction, without the necessity of showing
any actual damages or that money damages would not afford an adequate remedy, and without the necessity of posting any bond or other security.
The aforementioned equitable relief shall be in addition to, not in lieu of, legal remedies, monetary damages, or other available forms
of relief.

 

12.  [Reserved].

 

13.  Proprietary Rights.

 

13.1  Work Product.
The Consultant acknowledges and agrees that all right, title, and interest in and to all writings, works of authorship, technology, inventions,
discoveries, processes, techniques, methods, ideas, concepts, research, proposals, materials, and all other work product of any nature
whatsoever, that are created, prepared, produced, authored, edited, amended, conceived, or reduced to practice by the Consultant individually
or jointly with others during the provision of Consultant’s service to the Company and relate in any way to the business or contemplated
business, products, activities, research, or development of the Company or result from any work performed by the Consultant for the Company
(in each case, regardless of when or where prepared or whose equipment or other resources is used in preparing the same), all rights and
claims related to the foregoing, and all printed, physical and electronic copies, and other tangible embodiments thereof (collectively,
“Work Product”), as well as any and all rights in and to US and foreign (a) patents, patent disclosures and inventions
(whether patentable or not), (b) trademarks, service marks, trade dress, trade names, logos, corporate names, and domain names, and other
similar designations of source or origin, together with the goodwill symbolized by any of the foregoing, (c) copyrights and copyrightable
works (including computer programs), mask works, and rights in data and databases, (d) trade secrets, know-how, and other confidential
information, and (e) all other intellectual property rights, in each case whether registered or unregistered and including all registrations
and applications for, and renewals and extensions of, such rights, all improvements thereto and all similar or equivalent rights or forms
of protection in any part of the world (collectively, “Intellectual Property Rights”), shall be the sole and exclusive
property of the Company.

 

    8

     

    

 

For purposes of this Agreement, Work
Product includes, but is not limited to, Group information, including plans, publications, research, strategies, techniques, agreements,
documents, contracts, terms of agreements, negotiations, know-how, computer programs, computer applications, software design, web design,
work in process, databases, manuals, results, developments, reports, graphics, drawings, sketches, market studies, formulae, notes, communications,
algorithms, product plans, product designs, styles, models, audiovisual programs, inventions, unpublished patent applications, original
works of authorship, discoveries, experimental processes, experimental results, specifications, customer information, client information,
customer lists, client lists, manufacturing information, marketing information, advertising information, and sales information.

 

13.2  Work Made for
Hire; Assignment. The Consultant acknowledges that, by reason of being employed by the Company at the relevant times, to the extent
permitted by law, all of the Work Product consisting of copyrightable subject matter is “work made for hire” as defined in
17 U.S.C. § 101 and such copyrights are therefore owned by the Company. To the extent that the foregoing does not apply, the Consultant
hereby irrevocably assigns to the Company, for no additional consideration, the Consultant’s entire right, title, and interest in
and to all Work Product and Intellectual Property Rights therein, including the right to sue, counterclaim, and recover for all past,
present, and future infringement, misappropriation, or dilution thereof, and all rights corresponding thereto throughout the world. Nothing
contained in this Agreement shall be construed to reduce or limit the Company’s rights, title, or interest in any Work Product or
Intellectual Property Rights so as to be less in any respect than that the Company would have had in the absence of this Agreement.

 

13.3  Further Assurances;
Power of Attorney. During and after Consultant’s service, the Consultant agrees to reasonably cooperate with the Company to
(a) apply for, obtain, perfect, and transfer to the Company the Work Product as well as any and all Intellectual Property Rights in the
Work Product in any jurisdiction in the world; and (b) maintain, protect and enforce the same, including, without limitation, giving testimony
and executing and delivering to the Company any and all applications, oaths, declarations, affidavits, waivers, assignments, and other
documents and instruments as shall be requested by the Company. The Consultant hereby irrevocably grants the Company power of attorney
to execute and deliver any such documents on the Consultant’s behalf in Consultant’s name and to do all other lawfully permitted
acts to transfer the Work Product to the Company and further the transfer, prosecution, issuance, and maintenance of all Intellectual
Property Rights therein, to the full extent permitted by law, if the Consultant does not promptly cooperate with the Company’s request
(without limiting the rights the Company shall have in such circumstances by operation of law). The power of attorney is coupled with
an interest and shall not be affected by the Consultant’s subsequent incapacity.

 

13.4  No License.
The Consultant understands that this Agreement does not, and shall not be construed to, grant the Consultant any license or right of any
nature with respect to any Work Product or Intellectual Property Rights or any Confidential Information, materials, software, or other
tools made available to Consultant by the Company.

 

14. Security.

 

14.1  Security and
Access. The Consultant agrees and covenants (a) to comply with all Group security policies and procedures as in force from time to
time including without limitation those regarding computer equipment, telephone systems, voicemail systems, facilities access, monitoring,
key cards, access codes, Group intranet, internet, social media and instant messaging systems, computer systems, e-mail systems, computer
networks, document storage systems, software, data security, encryption, firewalls, passwords and any and all other Group facilities,
IT resources and communication technologies (“Facilities and Information Technology Resources”); (b) not to access
or use any Facilities and Information Technology Resources except as authorized by the Company; and (iii) not to access or use any Facilities
and Information Technology Resources in any manner after the termination of the Consultant’s service by the Company, whether termination
is voluntary or involuntary. The Consultant agrees to notify the Company promptly in the event Consultant learns of any violation of the
foregoing by others, or of any other misappropriation or unauthorized access, use, reproduction, or reverse engineering of, or tampering
with any Facilities and Information Technology Resources or other Group property or materials by others.

 

    9

     

    

 

14.2  Exit Obligations.
Upon (a) voluntary or involuntary termination of the Consultant’s service or (b) the Company’s request at any time during
the Consultant’s service, the Consultant shall (i) provide or return to the Company any and all Group property, including keys,
key cards, access cards, identification cards, security devices, employer credit cards, network access devices, computers, cell phones,
smartphones, PDAs, pagers, fax machines, equipment, speakers, webcams, manuals, reports, files, books, compilations, work product, e-mail
messages, recordings, tapes, disks, thumb drives or other removable information storage devices, hard drives, negatives, and data and
all Group documents and materials belonging to the Company and stored in any fashion, including but not limited to those that constitute
or contain any Confidential Information or Work Product, that are in the possession or control of the Consultant, whether they were provided
to the Consultant by the Group or any of its business associates or created by the Consultant in connection with Consultant’s service
to the Company; and (ii) delete or destroy all copies of any such documents and materials not returned to the Company that remain in the
Consultant’s possession or control, including those stored on any non- Group devices, networks, storage locations, and media in
the Consultant’s possession or control.

 

15.  Publicity. The Consultant
hereby irrevocably consents to any and all uses and displays, by the Group and its agents, representatives and licensees, of the Consultant’s
name, voice, likeness, image, appearance, and biographical information in, on or in connection with any pictures, photographs, audio and
video recordings, digital images, websites, television programs and advertising, other advertising and publicity, sales and marketing
brochures, books, magazines, other publications, CDs, DVDs, tapes, and all other printed and electronic forms and media throughout the
world, at any time during or after the period of Consultant’s service to the Company, for all legitimate commercial and business
purposes of the Group (“Permitted Uses”) without further consent from or royalty, payment, or other compensation to
the Consultant. The Consultant hereby forever waives and releases the Group and its directors, officers, Consultants, and agents from
any and all claims, actions, damages, losses, costs, expenses, and liability of any kind, arising under any legal or equitable theory
whatsoever at any time during or after the period of Consultant’s service to the Company, arising directly or indirectly from the
Group’s and its agents’, representatives’, and licensees’ exercise of their rights in connection with any Permitted
Uses.

 

16. Governing Law: Jurisdiction
and Venue. This Agreement, for all purposes, shall be construed in accordance with the laws of Delaware without regard to conflicts
of law principles. Any action or proceeding by either of the parties to enforce this Agreement shall be brought exclusively in a state
or federal court located in New York County, New York. The parties hereby irrevocably submit to the exclusive jurisdiction of such courts
for purposes of this Agreement and waive the defense of inconvenient forum to the maintenance of any such action or proceeding in such
venue.

 

17.  Entire Agreement. Unless
specifically provided herein, this Agreement contains all of the understandings and representations between the Consultant and the Company
pertaining to the subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations and warranties,
both written and oral, with respect to such subject matter. The parties mutually agree that the Agreement can be specifically enforced
in court and can be cited as evidence in legal proceedings alleging breach of the Agreement.

 

19.  Modification and Waiver.
No provision of this Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by
the Consultant and by the Chairman of the Company’s Board of Directors as directed by the Board and the Compensation Committee.
No waiver by either of the parties of any breach by the other party hereto of any condition or provision of this Agreement to be performed
by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or any prior or subsequent
time, nor shall the failure of or delay by either of the parties in exercising any right, power, or privilege hereunder operate as a waiver
thereof to preclude any other or further exercise thereof or the exercise of any other such right, power, or privilege.

 

20.  Severability. Should
any provision of this Agreement be held by a court of competent jurisdiction (or pursuant to arbitration under Section 12) to be enforceable
only if modified, or if any portion of this Agreement shall be held as unenforceable and thus stricken, such holding shall not affect
the validity of the remainder of this Agreement, the balance of which shall continue to be binding upon the parties with any such modification
to become a part hereof and treated as though originally set forth in this Agreement.

 

The parties further agree that any such court
is expressly authorized to modify any such unenforceable provision of this Agreement in lieu of severing such unenforceable provision
from this Agreement in its entirety, whether by rewriting the offending provision, deleting any or all of the offending provision, adding
additional language to this Agreement, or by making such other modifications as it deems warranted to carry out the intent and agreement
of the parties as embodied herein to the maximum extent permitted by law.

 

    10

     

    

 

The parties expressly agree that this Agreement
as so modified shall be binding upon and enforceable against each of them. In any event, should one or more of the provisions of this
Agreement be held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not
affect any other provisions hereof, and if such provision or provisions are not modified as provided above, this Agreement shall be construed
as if such invalid, illegal, or unenforceable provisions had not been set forth herein.

 

21.  Captions. Captions and
headings of the sections and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to
be construed by reference to the caption or heading of any section or paragraph.

 

22.  Counterparts. This Agreement
may be executed in separate counterparts, each of which shall be deemed an original, but all of which taken together shall constitute
one and the same instrument.

 

23.  Tolling. Should the
Consultant violate any of the terms of the restrictive covenant obligations articulated herein, the obligation at issue will run from
the first date on which the Consultant ceases to be in violation of such obligation.

 

24.  Notification to Subsequent
Employer. When the Consultant’s service with the Company terminates, the Consultant agrees to notify any subsequent employer
of the restrictive covenants sections contained in this Agreement. The Consultant will also deliver a copy of such notice to the Company
before the Consultant commences Consulting with any subsequent employer. In addition, the Consultant authorizes the Company to provide
a copy of the restrictive covenants sections of this Agreement to third parties, including but not limited to, the Consultant’s
subsequent, anticipated, or possible future employer.

 

25.  Successors and Assigns.
This Agreement is personal to the Consultant and shall not be assigned by the Consultant. Any purported assignment by the Consultant shall
be null and void from the initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether
direct or indirect, by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets of the Company.
This Agreement shall inure to the benefit of the Company and permitted successors and assigns.

 

26.  Notice. Notices and
all other communications provided for in this Agreement shall be in writing and shall be delivered personally or sent by registered or
certified mail, return receipt requested, or by overnight carrier to the parties at the addresses set forth below (or such other addresses
as specified by the parties by like notice):

 

If to the Company:

 

Mainz Biomed B.V.

Robert Koch Strasse 50

55129 Mainz, Germany

Attn: Guido Baechler

 

If to the Consultant:

 

William Caragol

[address]

Email: bill@quidemllc.com 

 

27.  Representations of the Consultant.
The Consultant represents and warrants to the Company that:

 

The Consultant’s acceptance of Consulting
with the Company and the performance of Consultant’s duties hereunder will not conflict with or result in a violation of, a breach
of, or a default under any contract, agreement, or understanding to which Consultant is a party or is otherwise bound. The Consultant’s
acceptance of Consulting with the Company and the performance of Consultant’s duties hereunder will not violate any non-solicitation,
non-competition, or other similar covenant or agreement of a prior employer.

 

28.  Withholding. The Company
shall have the right to withhold from any amount payable hereunder any Federal, state, and local taxes in order for the Company to satisfy
any withholding tax obligation it may have under any applicable law or regulation.

 

29. Survival. Upon the expiration
or other termination of this Agreement, the respective rights and obligations of the parties hereto shall survive such expiration or other
termination to the extent necessary to carry out the intentions of the parties under this Agreement.

 

30. Acknowledgement of Full Understanding.
THE CONSULTANT ACKNOWLEDGES AND AGREES THAT CONSULTANT HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE CONSULTANT
ACKNOWLEDGES AND AGREES THAT CONSULTANT HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF CONSULTANT’S CHOICE
BEFORE SIGNING THIS AGREEMENT.

 

[SIGNATURE PAGE TO FOLLOW]

 

    11

     

    

 

IN WITNESS WHEREOF, the parties hereto have executed
this Agreement as of the date first above written.

 

	 	Mainz Biomed B.V.
	 	 
	 	By	 
	 	Name: 	 
	 	Title: 	 

 

	CONSULTANT	 
	 	 
	Signature: 	 	 
	Print Name:	 	 

 

 

12Exhibit 10.6

 

	Geschäftsführer-Dienstvertrag

     

    zwischen

     

    der
    Mainz Biomed B.V. mit Sitz in Amsterdam, Geschäftsanschrift: Robert-Koch-Str. 50, 55129 Mainz, vertreten durch die Gesellschafterversammlung,
    diese wiederum vertreten durch Herrn Marco Messina,

     

    –
    nachfolgend auch: „Gesellschaft“ –

     

    und

     

    Herrn
    Dr. Moritz Eidens, Am Emmerling Park 22, 55218 Ingelheim,

     

    –
    nachfolgend auch: „Geschäftsführer“ –

     

    –
    nachfolgend beide gemeinsam: „die Parteien“ – 
	Management
                                            Services Agreement

     

    between

     

    Mainz
    Biomed B.V. based in Amsterdam, company address: Robert-Koch-Str. 50, 55129 Mainz, Germany, represented by the shareholders’
    meeting, which is in turn represented by Mr Marco Messina,

     

    –
    hereinafter also referred to as ’Company’ –

     

    and

     

    Dr
    Moritz Eidens, Am Emmerling Park 22, 55218 Ingelheim, Germany,

     

    –
    hereinafter also referred to as ’Director‘ –

     

    –
    hereinafter both together referred to as ‘the Parties’ –

	Präambel

     

    Herr
    Dr. Eidens ist Geschäftsführer der PharmGenomics GmbH mit Sitz in Mainz, eingetragen im Handelsregister des Amtsgerichts
    Mainz unter HRB 41529. Er hat dieses Unternehmen im Jahr 2008 als Gesellschafter mitgegründet und hält derzeit noch ca.
    11,5% der Geschäftsanteile.

     

    Die
    Mainz Biomed B.V. ist eine Gesellschaft mit beschränkter Haftung nach niederländischem Recht (besloten vennootschap met
    beperkte aansprakelijkheid – B.V.) und hat ihren Sitz in Amsterdam. Sie ist im Handelsregister der Niederlande unter der Nummer
    82116296 eingetragen.
	Preamble

     

    Dr
    Eidens is Managing Director of PharmGenomics GmbH, which is based in Mainz and registered in the Commercial Register of the Local
    Court of Mainz under HRB 41529. He co-founded this company in 2008 as a shareholder and currently still holds approximately 11.5%
    of the shares.

     

    Mainz
    Biomed B.V. is a limited liability company under Dutch law (besloten vennootschap met beperkte aansprakelijkheid – B.V.) and
    has its registered office in Amsterdam. It is registered in the commercial register of the Netherlands under number 82116296.

 

    page 1 of 13

     

    

 

	Die
                                            Gesellschafter der PharmGenomics GmbH werden auf der Grundlage des „Contribution Agreements“
                                            vom [Datum] ihre Geschäftsanteile gegen Geschäftsanteile der Mainz Biomed B.V.
                                            tauschen und so zu Gesellschaftern der Mainz Biomed B.V. werden. Die PharmGenomics GmbH wird
                                            hierdurch eine 100%ige Tochtergesellschaft der Mainz Biomed B.V.

     

    Herr
    Dr. Eidens bleibt Geschäftsführer der PharmGenomics GmbH. Zudem ist beabsichtigt, dass die Gesellschafterversammlung Herrn
    Dr. Eidens gem. Ziff. 4.2 (b) (iv) des Contribution Agreements vom [Datum] zum Geschäftsführer der Mainz Biomed B.V. bestellt.

     

    Die
    Gesellschafter der Mainz Biomed B.V. beabsichtigen, die Gesellschaft in naher Zukunft in eine Aktiengesellschaft nach niederländischem
    Recht (naamloze vennootschap – N.V.) umzuwandeln und die Zulassung der Aktien der N.V. zur Notierung an der Nasdaq in New York
    zu beantragen. Zwischen den Parteien besteht Einigkeit, dass Herr Dr. Eidens mit dem Wirksamwerden der Umwandlung zum Vorstandsmitglied
    der N.V. bestellt werden wird (Wissenschaftlicher Vorstand / Chief Scientific Officer – CSO). Dieser Dienstvertrag wird –
    soweit rechtlich möglich – für das Dienstverhältnis mit der N.V. fortgelten. Die Parteien werden zeitnah die
    erforderlichen Anpassungen vornehmen, wobei Herrn Dr. Eidens mindestens die Konditionen gewährt werden, die dieser Dienstvertrag
    vorsieht.

     

    Die
    Parteien beabsichtigen allein, einen Dienstvertrag zu den in diesem Vertrag festgelegten Bedingungen abzuschließen. Es ist
    der ausdrückliche Wille der Parteien, keinen Arbeitsvertrag i.S.d. § 611a Abs. 1 BGB abzuschließen.

    
	The
                                            shareholders of PharmGenomics GmbH will exchange their shares for shares in Mainz Biomed
                                            B.V. on the basis of the "Contribution Agreement" of August 3, 2021 and thus become shareholders
                                            of Mainz Biomed B.V. PharmGenomics GmbH will thereby become a wholly-owned subsidiary of
                                            Mainz Biomed B.V.

     

    Dr
    Eidens will remain Managing Director of PharmGenomics GmbH. In addition, it is intended that the shareholders' meeting will appoint
    Dr Eidens as Director of Mainz Biomed B.V. pursuant to Section 4.2 (b) (iv) of the Contribution Agreement of August 3, 2021.

     

    The
    shareholders of Mainz Biomed B.V. intend to convert the Company into a stock corporation under Dutch law (naamloze vennootschap –
    N.V.) in the near future and to apply for admission of the shares of the N.V. to listing on Nasdaq in New York. The Parties agree
    that Dr Eidens will be appointed as a member of the Executive Board of N.V. (Chief Scientific Officer – CSO) upon the conversion
    becoming effective. This service agreement will – as far as legally possible – continue to apply to the service relationship
    with N.V. The Parties will make the necessary adjustments in a timely manner, whereby Dr Eidens will be granted at least the conditions
    provided for in this service agreement.

     

    The
    Parties only wish to enter into a service agreement under the terms and conditions as set out in this service agreement. It is the
    express intention of the Parties not to enter into an employment contract as defined in Section 611a Para. 1 of the German Civil
    Code (BGB).

    

 

    page 2 of 13

     

    

 

	Dies
                                            vorausgeschickt vereinbaren die Parteien was folgt:

                                                                     

                                                                    §
                                            1 Geschäftsführung / Vertretung

     

    (1)    Der
    Geschäftsführer führt die Gesellschaft nach Maßgabe der Gesetze, dieses Vertrags, des Gesellschaftsvertrags
    sowie der Bestimmungen der Gesellschafter.

     

    (2)    Inhalt
    und Umfang der Vertretungsbefugnis und Zeichnungsberechtigung des Geschäftsführers richten sich nach Maßgabe der
    Vorschriften des Gesellschaftsvertrags.
	Having
                                            said this, the Parties agree as follows:

                                                                                                                                            

                                                                                                                                           Sec.
                                            1 Management / Representation

     

    (1)    The
    Director shall run the Company in accordance with the statutes, this contract, the articles of association as well as the stipulations
    of the shareholders.

     

    (2)    The
    content and extent of the Director's powers of representation and signature are governed by the provisions of the articles of association.

	§
                                            2 Dienstzeit und -sitz

     

    (1)    Der
    Geschäftsführer stellt seine gesamte Arbeitskraft, fachlichen Kenntnisse und Erfahrungen der Gesellschaft und der PharmGenomics
    GmbH zur Verfügung. In seiner Zeiteinteilung ist der Geschäftsführer frei.

     

    (2)    Der
    Dienstsitz des Geschäftsführers ist dessen jeweiliger Wohnsitz. Eine Versetzung des Geschäftsführers an einen
    anderen Ort ist ohne seine Zustimmung nicht zulässig. Der Geschäftsführer ist in der Wahl seines Aufenthaltsorts während
    der Dienstausübung frei.
	Sec.
                                            2 Working time / Place of work

     

    (1)    The
    Director shall place his entire working capacity, professional knowledge and experience at the disposal of the Company and PharmGenomics
    GmbH. The Director shall be free in the allocation of his time.

     

    (2)    The
    place of business of the Director shall be his respective place of residence. A relocation of the Director to another place is not
    permissible without his consent. The Director shall be free to choose his place of work during the performance of his duties.

	§
                                            3 Vertragsdauer

     

    (1)    Dieser
    Dienstvertrag beginnt mit der Bestellung zum Geschäftsführer durch die Gesellschafterversammlung gem. Ziff. 4.2 (b) (iv)
    des Contribution Agreements vom [Datum] und wird auf drei Jahre geschlossen. Er verlängert sich jeweils um drei weitere Jahre,
    wenn er nicht von einer der Vertragsparteien mit einer Frist von sechs Monaten vor Ablauf des jeweiligen Verlängerungszeitraums
    gekündigt wird. 
	Sec.
                                            3 Term of contract

     

    (1)    This
    service agreement commences upon appointment as Director by the shareholders’ meeting pursuant to Section 4.2 (b) (iv) of the
    Contribution Agreement of [date] and is concluded for a term of three years. It shall extend by three years at a time if it is not
    terminated by one of the Parties with a notice period of six months prior to the respective extension period.

 

    page 3 of 13

     

    

 

	(2)    Während
                                            der Vertragsdauer gem. Abs. 1 ist eine ordentliche Kündigung dieses Dienstvertrags
                                            beiderseits ausgeschlossen. Das Recht zur außerordentlichen Kündigung aus wichtigem
                                            Grund (§ 626 BGB) bleibt unberührt.

     

    (3)    Jede
    Kündigung bedarf der Schriftform.

     

    (4)    Eine
    Kündigung des Geschäftsführers ist gegenüber einem weiteren Geschäftsführer oder dem Vorsitzenden der
    Gesellschafterversammlung zu erklären.

     

    (5)    Im
    Fall einer Kündigung der Gesellschaft gem. Abs. 1 ist der Geschäftsführer auf sein Verlangen bis zur Beendigung des
    Dienstverhältnisses unter Fortzahlung der Vergütung gem. § 4 dieses Dienstvertrags von der Erbringung der Dienstleistung
    freizustellen.

     

    (6)    Die
    Parteien sind sich einig, dass ein Beschluss der Gesellschafter, die gesellschaftsrechtliche Beziehung des Geschäftsführers
    zur Gesellschaft zu beenden, nicht das Ende des Dienstverhältnisses des Geschäftsführers mit der Gesellschaft zur
    Folge hat. In diesem Fall besteht dieser Dienstvertrag in vollem Umfang fort.
	(2)    During
                                            the term of the contract pursuant to Para. 1, termination of this service agreement shall
                                            be excluded by both parties. The right to termination for good cause (Section 626 of the
                                            German Civil Code – BGB) shall remain unaffected.

     

    (3)    Any
    notice of termination must be in writing.

     

    (4)    Notice
    of termination by the Director shall be given to another Director or to the Chairman of the shareholders’ meeting.

     

    (5)    In
    the event of termination by the Company pursuant to Para. 1, the Director shall, at his request, be released from his duties until
    the termination of the service relationship with continued payment of the remuneration pursuant to Section 4 of this service agreement.

     

    (6)    The
    Parties agree that a resolution taken by the shareholders of the Company to terminate the corporate law relationship of the Director
    with the Company does not imply the end of the service relationship of the Director with the Company. In that case this service agreement
    will continue to be in full force and effect.

 

    page 4 of 13

     

    

 

	§
                                            4 Vergütung

                                                                   

    (1)    Als
    Vergütung für seine Dienste erhält der Geschäftsführer ein Jahresgrundgehalt in Höhe von EUR 164.000,00
    brutto. Das Jahresgrundgehalt ist zahlbar in zwölf gleichen Raten, jeweils am Ende eines Kalendermonats sowie unter Abzug von
    Steuern und Sozialabgaben. Im Jahr des Eintritts und im Jahr des Austritts wird das Jahresgrundgehalt zeitanteilig gezahlt.

     

    (2)    Der
    Geschäftsführer ist zur Teilnahme am Equity Incentive Plan der Gesellschaft berechtigt und wird mindestens ein Achtel der
    im Rahmen des Equity Incentive Plan ausgegebenen Aktien erhalten.

     

    (3)    Für
    die Dauer dieses Dienstvertrags übernimmt die Gesellschaft bis zur Höhe der jeweils geltenden gesetzlichen Beitragsbemessungsgrundlage
    einen Betrag in Höhe des auf diesen Teilbetrag fiktiv entfallenden Arbeitgeberanteils an den Beiträgen zur privaten Kranken-
    und Pflegeversicherung des Geschäftsführers, höchstens jedoch in Höhe der Hälfte des Betrags, den der Geschäftsführer
    für seine Kranken- und Pflegeversicherung tatsächlich zu zahlen hat.
	Sec.
                                            4 Remuneration

                                                                                                                                      

    (1)    As
    remuneration for his services, the Director shall receive a fixed annual salary of EUR 164,000 gross. The fixed annual salary shall
    be payable in twelve equal installments at the end of a calendar month, less taxes and social security contributions. In the year
    of joining and in the year of leaving the Company, the fixed annual salary is paid pro rata temporis.

     

    (2)    The
    Director is entitled to participate in the Company's Equity Incentive Plan and will receive at least one eighth of the shares issued
    under the Equity Incentive Plan.

     

    (3)    For
    the duration of this service agreement, the Company shall bear, up to the amount of the statutory income threshold applicable at
    the time, an amount equal to the employer's share of the contributions to the Director's private health and nursing care insurance
    that is fictitiously attributable to this partial amount, but no more than half of the amount that the Director actually has to pay
    for his health and nursing care insurance.

	§
                                            5 Fortzahlung der Vergütung

                                                                                                                           

    (1)    Wird
    der Geschäftsführer durch Arbeitsunfähigkeit infolge Krankheit oder einem anderen von ihm nicht zu vertretenden Grund
    an der Erbringung seiner vertraglichen Leistung gehindert, wird ihm die Vergütung nach § 4 sechs Monate, längstens
    aber bis zur Beendigung des Dienstverhältnisses fortgezahlt. Etwaige aufgrund der Dienstverhinderung von den Trägern der
    gesetzlichen Krankenkasse oder einer privaten Krankenversicherung gewährte Leistungen werden auf die Vergütung angerechnet. 

     

    (2)    Im
    Fall des Todes des Geschäftsführers während der Dauer dieses Vertrags haben sein Ehepartner und seine unterhaltsberechtigten
    Kinder als Gesamtgläubiger Anspruch auf Fortzahlung der Vergütung gem. § 4 Abs. 1 für den Sterbemonat und die
    zwölf folgenden Monate, längstens aber bis zur Beendigung des Dienstverhältnisses.
	Sec.
                                            5 Continued payment of remuneration

                                                                                             

    (1)    Should
    the Director be prevented from rendering services pursuant to this contract due to an inability to work resulting from illness or
    another reason beyond his control, the remuneration pursuant to Section 4 shall continue to be paid for six months, but at most up
    to the end of the service relationship. Any benefits granted by the institutions of the statutory health insurance fund or a private
    health insurance fund due to the Director’s inability to work will be offset against the remuneration. 

     

    (2)    In
    the event of the Directors death during the term of this contract, his spouse and dependent children shall be entitled as joint and
    several creditors to continued payment of the remuneration pursuant to Section 4 Para. 1 for the month of death and the following
    twelve months, but at most up to the end of the service relationship.

 

    page 5 of 13

     

    

 

	§
                                            6 Abfindung

                                                                                                                           

    (1)    Im
    Fall einer Kündigung der Gesellschaft gem. § 3 Abs. 1 erhält der Geschäftsführer eine Abfindung in Höhe
    von drei durchschnittlichen Bruttomonatsvergütungen gem. § 4 für jedes zurückgelegte Dienstjahr, wobei auch die
    bei der PharmGenomics GmbH als Arbeitnehmer und Geschäftsführer zurückgelegten Dienstjahre einzubeziehen sind. Zeiträume
    von mehr als sechs Monaten werden für die Berechnung auf ein volles Dienstjahr aufgerundet.

     

    (2)    Für
    die Berechnung der durchschnittlichen Bruttomonatsvergütung wird die Vergütung gem. § 4 Abs. 1 und 2 während
    der letzten 60 Kalendermonate vor Ausspruch der Kündigung zugrunde gelegt. Hat das Dienstverhältnis noch keine 60 Kalendermonate
    bestanden, ist hinsichtlich der für die Berechnung fehlenden Kalendermonate die zuletzt von der PharmGenomics GmbH erhaltende
    Vergütung in Höhe von EUR 48.000,00 brutto zugrunde zu legen.

     

    (3)    Die
    Abfindung wird mit der Beendigung des Dienstverhältnisses zur Zahlung fällig.
	Sec.
                                            6 Severance payment

                                                                                             

    (1)    In
    the event of termination by the Company pursuant to Section 3 Para. 1, the Director shall receive a severance payment in the amount
    of three average gross monthly remunerations pursuant to Section 4 for each year of service completed, including the years of service
    as Employee and Managing Director of PharmGenomics GmbH. Periods of more than six months shall be rounded up to one full year of
    service for the purpose of calculation.

     

    (2)    The
    calculation of the average gross monthly remuneration shall be based on the remuneration pursuant to Section 4 Para. 1 and 2 during
    the last 60 calendar months prior to the notice of termination. If the service relationship has not yet existed for 60 calendar months,
    the remuneration last received by PharmGenomics GmbH in the amount of EUR 48,000 gross shall be taken as the basis with regard to
    the calendar months missing for the calculation.

     

    (3)    The
    severance payment shall become due for payment upon termination of the service relationship.

	§
                                            7 Dienstwagen

                                                                   

    (1)    Die
    Gesellschaft stellt dem Geschäftsführer auf sein Verlangen ein Dienstfahrzeug (Bruttolistenpreis bis maximal EUR 60.000,00
    oder monatliche Brutto-Leasingrate bis maximal EUR 500,00) zur dienstlichen und privaten Nutzung zur Verfügung.

     

    (2)   Die
    Kosten des Dienstwagens einschließlich aller Betriebskosten trägt die Gesellschaft. Die Einkommenssteuer auf den geldwerten
    Vorteil der Privatnutzung trägt der Geschäftsführer.
	Sec.
                                            7 Company Car

                                                                                                                                      

    (1)    At
    the request of the Director, the Company shall provide him with a company car (gross list price up to a maximum of EUR 60,000.00
    or monthly gross leasing rate up to a maximum of EUR 500.00) for business and private use.

     

    (2)    The
    costs of the company car including all operating costs are borne by the Company. Income tax on the imputed income for the private
    use shall be borne by the Director.

 

    page 6 of 13

     

    

 

 

	§
                                            8 Reisekosten / Spesen / sonstige Aufwendungen

                                                                   

    (1)    Für
    die Bewirtung von Geschäftspartnern und Geschäftsreisen hat der Geschäftsführer Anspruch auf Ersatz seiner angemessenen
    Auslagen, soweit sie dem Geschäftsführer im Interesse der Gesellschaft entstehen. Die Einzelheiten wird die Gesellschaft
    in einer Reisekosten- und Spesenrichtlinie für die Geschäftsführung festlegen.

     

    (2)    Die
    Gesellschaft stellt dem Geschäftsführer monatlich ein Budget in Höhe von EUR 400,00 für Arbeitsmittel (z.B. Dienst-PC,
    -Notebook, -Tablet, -Smartphone) und sonstige dienstliche Aufwendungen (z.B. Vertrags- und Verbindungskosten eines dienstlich genutzten
    Telefon-Anschlusses oder Mobilvertrags) zur Verfügung. Zusätzlich zu dem monatlichen Budget stellt die Gesellschaft dem
    Geschäftsführer zu Beginn des Dienstverhältnisses zur Einrichtung eines Home-Office-Arbeitsplatzes einmalig ein Budget
    von EUR 2.000,00 zur Verfügung.

     

    (3)    Die
    Gesellschaft stellt dem Geschäftsführer jährlich ein Budget in Höhe von EUR 5.000,00 für Kosten der Gesunderhaltung
    (z.B. Gesundheitsuntersuchungen, die nicht von der Krankenversicherung getragen werden, oder Physiotherapie/Massage-Anwendungen)
    zur Verfügung. Das am Ende eines Kalenderjahres nicht verbrauchte Budget verfällt mit Ablauf des jeweiligen Kalenderjahres.

     

    (4)    Die
    Gesellschaft stellt dem Geschäftsführer jährlich ein Fortbildungsbudget zur Verfügung. Einzelheiten wird die
    Gesellschaft in einer Fortbildungsrichtlinie für die Geschäftsführung festlegen. 

     

    (5)    Die
    Gesellschaft stellt dem Geschäftsführer zur Deckung der Aufwendungen gem. Abs. 1 bis 4 eine Firmenkreditkarte zur Verfügung.
	Sec.
                                            8 Travel costs / Expenses / other costs

     

    (1)    For
    entertaining business partners and for business trips, the Director is entitled to reimbursement of his reasonable expenses to the
    extent these are incurred to the Director in the interests of the Company. The Company will define details in a travel and expense
    policy for the Board of Directors.

     

    (2)    The
    Company shall provide the Director with a monthly budget of EUR 400.00 for work equipment (e.g. company PC, notebook, tablet, smartphone)
    and other business expenses (e.g. contract and connection costs for a telephone connection or mobile phone contract used for business
    purposes). In addition to the monthly budget, the Company shall provide the Director with a one-time budget of EUR 2,000.00 at the
    beginning of the service relationship to set up a home office.

     

    (3)    The
    Company shall provide the Director with an annual budget of EUR 5,000 for health care costs (e.g. health examinations not covered
    by health insurance or physiotherapy/massage treatments). The budget not used at the end of a calendar year lapses at the end of
    the respective calendar year.

     

    (4)    The
    Company shall provide the Director with an annual training budget. The Company will define details in a training policy for the Board
    of Directors. 

     

    (5)    The
    Company shall provide the Director with a company credit card to cover the expenses pursuant to Paras. 1 to 4.

 

    page 7 of 13

     

    

 

	§
                                            9 Versicherungen

                                                     

    (1)    Die
    Gesellschaft schließt für die Dauer dieses Vertrags zugunsten des Geschäftsführers eine Unfallversicherung für
    Berufsunfälle und Unfälle des täglichen Lebens mit Deckungssummen von EUR 500.000,00 für den Todesfall und EUR
    1.000.000,00 für den Invaliditätsfall ab.

     

    Bezugsberechtigt
    aus der Versicherung sind im Invaliditätsfall der Geschäftsführer, im Todesfall die von ihm benannten Personen, bei
    Fehlen einer solchen Bestimmung seine Erben.

     

    (2)    Die
    Gesellschaft versichert den Geschäftsführer auf ihre Kosten gegen Ansprüche, insbesondere Schadensersatzansprüche,
    die der Gesellschaft und/oder Dritten gegen den Geschäftsführer aufgrund oder im Zusammenhang mit seiner Tätigkeit
    zustehen können mit einer Deckungssumme von EUR 5.000.000,00 pro Schadensfall („D&O-Versicherung“). Der Versicherungsschutz
    schließt hinsichtlich des Verschuldensgrades lediglich wissentlich begangene Pflichtverletzungen vom Versicherungsschutz aus.
    Die Rückwärtsversicherung ist unbegrenzt und es wird eine mindestens 5-jährige unverfallbare Nachmeldefrist vereinbart.

     

    Die
    Gesellschaft gewährt dem Geschäftsführer jederzeit auf Verlangen Einsicht in die Versicherungsunterlagen und legt
    die Belege über die Prämienzahlungen vor. Diese Verpflichtung gilt auch nach Beendigung dieses Dienstvertrags. 
	Sec.
                                            9 Insurances

                                                                                                                        

    (1)    The
    Company shall take out accident insurance for the Director against work-related accidents and accidents in daily life for the duration
    of this contract with a coverage of EUR 500,000 for death and EUR 1,000,000 for invalidity.

     

    In
    case of invalidity, the Director is entitled to the benefits ensuing from the insurance coverage, in the case of death, the persons
    appointed by him, and in the absence of such an appointment, his heirs.

     

    (2)    The
    Company shall insure the Director at its own expense against claims, in particular damages claims, to which the Company and/or third
    parties could be entitled due to or in connection with the Director’s activities, with a coverage of EUR 5,000,000 per damage
    event (‘D&O insurance’). The insurance protection shall exclude, with regard to the degree of fault, mere breaches
    of duty that were knowingly committed from the insurance coverage. The retroactive insurance coverage is unlimited, and a vested
    extended reporting period of at least five years shall be agreed upon.

     

    The
    Company shall allow the Director, upon his request at any time, to inspect the insurance documents and present the receipts for the
    premium payments. This obligation shall survive this service agreement.

 

    page 8 of 13

     

    

 

	§
                                            10 Urlaub

                                                                   

    (1)    Der
    Geschäftsführer hat Anspruch auf einen bezahlten Jahresurlaub von 30 Arbeitstagen, wobei der Samstag nicht als Arbeitstag
    zählt. Der Urlaub ist unter Berücksichtigung der Interessen der Gesellschaft im Einvernehmen mit den anderen Geschäftsführern
    festzulegen.

     

    (2)    Soweit
    Urlaub im Lauf eines Kalenderjahres nicht genommen werden kann, wird er auf das nächste Jahr übertragen. Ein Verfall von
    Urlaubsansprüchen ist ausgeschlossen.

     

    (3)    Für
    das Jahr, in dem das Dienstverhältnis beginnt, steht dem Geschäftsführer für jeden angefangenen Monat des Bestehens
    des Dienstverhältnisses 1/12 des Jahresurlaubs gem. Abs. 1 zu. Zusätzlich hat er Anspruch auf den im Zeitpunkt des Beginns
    dieses Dienstverhältnisses noch bestehenden Resturlaub bei der PharmGenomics GmbH, der damit als abgegolten gilt.
	Sec.
                                            10 Vacation

                                                                                                                                      

    (1)    The
    Director shall have a claim to paid annual vacation of 30 working days, whereby Saturday shall not count as a working day. The vacation
    periods shall be determined in consultation with the other Directors, taking into account the interests of the Company.

     

    (2)    If
    vacation cannot be taken in the course of a calendar year, it shall be carried over to the next year. There shall be no forfeiture
    of vacation entitlements.

     

    (3)    For
    the year in which the service relationship commences, the Director shall be entitled to 1/12 of the annual vacation pursuant to Para.
    1 for each month or part thereof of the service relationship. In addition, he shall be entitled to the remaining vacation at PharmGenomics
    GmbH at the time of commencement of this service relationship, which shall be deemed to be compensated hereby.

	§
                                            11 Change of Control

                                                                                                                           

    (1)    Der
    Geschäftsführer hat für den Fall, dass es während der Vertragslaufzeit zu einem Change of Control i.S.d. nachfolgenden
    Abs. 2 kommt, das Recht, sein Amt als Geschäftsführer niederzulegen und das Dienstverhältnis außerordentlich
    mit einer Frist von sechs Monaten zum Monatsende zu kündigen. 
	Sec.
                                            11 Change of Control

                                                                                             

    (1)    In
    the event of a change of control within the meaning of Para. 2 below during the term of the contract, the Director shall be entitled
    to resign from office as Director and to terminate the service relationship with extraordinary notice of six months to the end of
    the month. 

 

    page 9 of 13

     

    

 

	(2)    Ein
                                            Change of Control im Sinne dieses Vertrags liegt vor, wenn

                                                     

    -    ein
    Dritter oder mehrere gemeinsam handelnde Dritte, die im Zeitpunkt des Vertragsschlusses nicht oder mit weniger als 50 % der Stimmrechte
    an der Gesellschaft beteiligt ist/sind, mindestens 50 % + 1 der Stimmrechte an der Gesellschaft erwerben bzw. erreichen, sei es durch
    Anteilsbesitz oder auf andere Weise, oder das Recht oder die Befähigung hat/haben, (a) eine solche Anzahl an Mitgliedern der
    Geschäftsführung oder eines vergleichbaren Organs der Gesellschaft zu bestellen oder abzuberufen oder (b) die Bestellung
    oder Abberufung einer solchen Anzahl an Mitgliedern anzuweisen, die erforderlich ist, um die für verbindliche Entscheidungen
    erforderliche Stimmenmehrheit in diesem Organ zu erreichen;

     

    -     eine
    Spaltung, Verschmelzung oder Übertragung des Vermögens der Gesellschaft auf einen dritten Rechtsträger unter Auflösung
    der Gesellschaft stattgefunden hat,

     

    -     die
    Gesellschaft Bestandteile ihres Vermögens im Umfang von mehr als 50 % des Wertes des Anlagevermögens veräußert
    oder überträgt. 
	(2)    A
                                            change of control within the meaning of this contract shall exist if

                                                                                                                        

    -    a
    third party or several third parties acting jointly, which at the time of the conclusion of the agreement do not hold or hold less
    than 50% of the voting rights in the Company, acquire or reach at least 50% + 1 of the voting rights in the Company, whether through
    ownership or otherwise, or has the rights or ability to (a) appoint or remove or (b) direct the appointment or removal of, such number
    of members of the management board or a similar body of the Company with decisive voting power in such body;

     

    -     a
    division, merger or transfer of the assets of the Company to a third legal entity has taken place with the Company as disappearing
    entity,

     

    -     the
    Company sells or transfers components of its assets amounting to more than 50% of the value of the fixed assets. 

 

    page 10 of 13

     

    

 

 

	(3)    Die
                                            Kündigung in Ausübung des Kündigungsrechts gem. Abs. 1 ist innerhalb einer
                                            Frist von sechs Monaten nach dem Ende des Kalendermonats zu erklären, in dem

                                                                   

    -     im
    Fall einer Änderung der Stimmrechtsverhältnisse die Stimmrechtsänderung nach den jeweils einschlägigen rechtlichen
    Vorschriften veröffentlicht worden ist,

     

    -    bei
    einer Verschmelzung, Vermögensübertragung oder bei Abschluss eines Beherrschungs- bzw. Gewinnabführungsvertrags die
    Eintragung in das Handelsregister der Gesellschaft erfolgt ist,

     

    -    bei
    einer rechtsgeschäftlichen Übertragung des Vermögens der dingliche Vollzug des Kaufvertrags stattgefunden hat.

     

    (4)    Im
    Fall der berechtigten Ausübung des Sonderkündigungsrechts gem. Abs. 1 zahlt die Gesellschaft dem Geschäftsführer
    eine einmalige Entschädigung in Höhe des Jahresgrundgehalts gem. § 4 Abs. 1 dieses Dienstvertrags, das ohne Ausübung
    des Sonderkündigungsrechts in dem Zeitraum nach der Beendigung des Dienstvertrags bis zum regulären Ende des Dienstvertrags
    gem. § 2 Abs. 1 zu zahlen gewesen wäre. Zudem hat der Geschäftsführer Anspruch auf die Abfindung gem. §
    6 dieses Dienstvertrags.
	(3)     Notice
                                            of termination in exercise of the right of termination pursuant to Para. 1 shall be given
                                            within a period of six months after the end of the calendar month in which

                                                                                                                                      

    -    in
    the case of a change in voting rights, the change in voting rights has been published in accordance with the relevant legal provisions,

     

    -    in
    the case of a merger, transfer of assets or conclusion of a control or profit transfer agreement, the entry has been made in the
    Commercial Register of the Company,

     

    -    in
    the case of a legal transfer of assets, the in rem execution of the purchase agreement has taken place.

     

    (4)    In
    the event of the justified exercise of the extraordinary right of termination pursuant to Para. 1, the Company shall pay the Director
    a one-time compensation in the amount of the fixed annual salary pursuant to Section 4 Para. 1 of this service agreement which would
    have been payable without the exercise of the extraordinary right of termination in the period after the termination of the service
    agreement until the regular end of the service agreement pursuant to Section 2 Para. 1. In addition, the Director is entitled to
    the severance payment pursuant to Section 6 of this service agreement.

 

    page 11 of 13

     

    

 

	§
                                            12 Wettbewerbsverbot

                                                     

    Dem
    Geschäftsführer ist es untersagt, während der Dauer dieses Vertrags in selbstständiger, unselbstständiger
    oder sonstiger Weise für ein Unternehmen tätig zu werden, welches mit der Gesellschaft in direktem oder indirektem Wettbewerb
    steht oder mit einem Wettbewerbsunternehmen i.S.v. § 15 AktG verbunden ist. In gleicher Weise ist es dem Geschäftsführer
    untersagt, während der Dauer dieses Verbots ein solches Unternehmen zu errichten, zu erwerben oder sich hieran unmittelbar oder
    mittelbar zu beteiligen, es sei denn, der Anteilsbesitz ermöglicht keinen Einfluss auf die Organe des betreffenden Unternehmens.
    Das Wettbewerbsverbot gilt auch zugunsten von mit der Gesellschaft i.S.v. § 15 AktG verbundenen Unternehmen.
	Sec.
                                            12 Covenant not to compete

                                                                                                                        

    The
    Director shall be prohibited from working for a company during the term of this contract on a freelance, dependent or other basis
    that is in direct or indirect competition with the Company or is affiliated with a competitive company within the meaning of Section
    15 of the German Stock Corporation Act (Aktiengesetz – AktG). In the same way, the Director shall be prohibited from forming,
    acquiring or directly or indirectly participating in such a company during the term of this contract unless his shareholding does
    not enable him to exert influence over the governing bodies of the company in question. The covenant not to compete shall also apply
    to the benefit of affiliates of the Company within the meaning of Section 15 of the German Stock Corporation Act (Aktiengesetz –
    AktG).

	§
                                            13 Geheimhaltung

                                                                                                             

    Der
    Geschäftsführer ist verpflichtet, gegenüber Dritten über alle vertraulichen Angelegenheiten der Gesellschaft,
    insbesondere Betriebs- und Geschäftsgeheimnisse, Stillschweigen zu bewahren.
	Sec.
                                            13 Confidentiality

                                                                               

    The
    Director shall be obligated to maintain secrecy vis-à-vis third parties with respect to all confidential matters of the Company,
    in particular trade and business secrets.

	§
                                            14 Rückgabe von Unterlagen und Arbeitsmitteln

                                                                                                             

    Der
    Geschäftsführer hat nach Beendigung des Dienstverhältnisses alle die Angelegenheiten der Gesellschaft betreffenden
    Unterlagen und alle etwaig überlassenen Arbeitsmittel unaufgefordert an die Gesellschaft zurückzugeben.
	Sec.
                                            14 Return of documents and working equipment

                                                                               

    After
    termination of the service relationship, the Director shall return to the Company, without being asked to do so, all documents relating
    to the affairs of the Company as well as any work equipment that may have been provided.

 

    page 12 of 13

     

    

 

	§
                                            15 Schlussbestimmungen

                                                     

    (1)    Änderungen
    und Ergänzungen dieses Dienstvertrags bedürfen zu ihrer Wirksamkeit der Schriftform. Gleiches gilt für die Aufhebung
    dieses Schriftformerfordernisses.

     

    (2)    Sollten
    einzelne Bestimmungen dieses Dienstvertrags ganz oder teilweise unwirksam sein oder werden, soll hierdurch die Wirksamkeit der übrigen
    Bestimmungen nicht berührt werden. Die Parteien sind im Fall einer unwirksamen Bestimmung verpflichtet, über eine wirksame
    und zumutbare Ersatzregelung zu verhandeln, die dem von den Parteien mit der unwirksamen Bestimmung verfolgten wirtschaftlichen Zweck
    möglichst nahekommt.

     

    (3)    Dieser
    Dienstvertrag unterliegt deutschem Recht.

     

    (4)    Ausschließlicher
    Gerichtsstand für alle Streitigkeiten zwischen der Gesellschaft und dem Geschäftsführer ist Mainz, Deutschland.

     

    (5)    Dieser
    Dienstvertrag wird in deutscher und englischer Fassung ausgefertigt. Die Parteien sind sich darüber einig, dass die englische
    Fassung lediglich der Information dient. Die deutsche Fassung ist rechtlich bindend.
	Sec.
                                            15 Final provisions

                                                                                                                        

    (1)    Changes
    or amendments to this service agreement must be in writing in order to be valid. The same applies to the cancellation of this written
    form requirement.

     

    (2)    Should
    any provisions of this service agreement be or become wholly or partially invalid, this shall not affect the validity of the remaining
    provisions. In the event of an invalid provision, the Parties shall be obliged to negotiate an effective and reasonable replacement
    provision which comes as close as possible to the economic purpose pursued by the Parties with the invalid provision.

     

    (3)    This
    service agreement shall be governed by German law.

     

    (4)    The
    exclusive place of jurisdiction for all disputes between the Company and the Director shall be Mainz, Germany.

     

    (5)    This
    service agreement shall be executed in German and English. The Parties agree that the English version is for information purposes
    only. The German version shall be legally binding.

 

	Mainz
    Biomed B.V.	 	Dr
    Moritz Eidens
	 	 	 
	 	 	 
	 	 	 
	Place, date	 	Place, date
	 	 	 
	 	 	 
	 	 	 
	Marco Messina	 	Dr Moritz Eidens

 

 

page
13 of 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]